CGEO H1 2026 Results Presentation

Page 1

GEORGIA CAPITAL 2Q26 & 1H26 RESULTS CALL PRESENTATION 4 AUGUST 2026

Page 2

01 2Q26 & 1H26 PERFORMANCE OVERVIEW GCAP RESULTS OVERVIEW AGGREGATED PORTFOLIO RESULTS OVERVIEW 02 DEEP DIVE INTO PRIVATE LARGE PORTFOLIO COMPANIES 03 2Q26 & 1H26 PORTFOLIO VALUATION OVERVIEW 04 LIQUIDITY AND DIVIDEND INCOME OUTLOOK 05 WRAP-UP 06 ANNEX CONTENTS 2 2

Page 3

6 5 3 2 1 NAV per share increased by 13.1% q-o-q to a record high of GEL 175.12 (up 15.6% q-o-q to GBP 50.10), driven by strong operating performances across our large private portfolio companies and continued growth in Lion Finance Group PLC’s share price 4 3 KEY DEVELOPMENTS Disposal of our housing development business, in line with our capital-light investment strategy, while also strengthening GCAP’s risk profile. Total net debt of the emerging and other businesses (ex. renewable energy) declined c.49% (by c.US$ 39 million), with net debt-to-EBITDA improving from 3.8x to 2.0x Accelerated revenue growth across our large private portfolio companies, with aggregate revenues up 19.1% y-o-y in 2Q26, compared to 14.3% in 2Q25, extending the delivery of double-digit growth to eight consecutive quarters NCC ratio improved by 6.8 ppts q-o-q to a record-low -2.9% as of 30 June 2026, marking our strongest capital position to date, driven by robust cash generation and continued portfolio value creation S&P Global Ratings upgraded GCAP’s corporate credit rating from BB- (Positive) to BB (Stable), bringing the rating fully in line with Georgia’s sovereign credit rating Completion of the GEL 700 million capital return programme significantly ahead of schedule through the early redemption of local sustainability-linked bonds and the extension of the existing share buyback programme 7 Commencement of a new GEL 1 billion capital allocation programme through the end of 2029, starting with a launch of initial US$ 50 million share buyback and cancellation programme

Page 4

NAV per share 31-Mar-26 Lion Finance Group Operating performance FX & multiple change Emerging & other portfolio Buybacks Operating expenses Liquidity manag. /FX/Other NAV per share 30-Jun-26 NAV PER SHARE (GEL) MOVEMENT IN 2Q26 NAV PER SHARE (GEL) UP 13.1% Q-O-Q TO GEL 175.12 IN 2Q26 ▪ The increase in NAV per share (GEL) reflects excellent underlying operating performances across the large portfolio companies, as well as continued growth in Lion Finance Group’s share price ▪ In 2Q26, GCAP delivered IFRS net income of GEL 710.1 million in GBP: 43.34 +15.6% +9.4% +13.1%-0.3%+2.2% +0.3% 4 in GBP: 50.10 -0.9%+2.4% PRIVATE LARGE PORTFOLIO 0.0% 154.82 175.12

Page 5

AS OF 30 JUNE 2026, FIVE-YEAR NAV PER SHARE CAGR STOOD AT 26.3%, 30.9% AND 32.1% IN GEL, US$ AND GBP TERMS, RESPECTIVELY AS OF 30 JUNE 2026, THREE-YEAR NAV PER SHARE CAGR STOOD AT 33.7%, 33.2% AND 31.3% IN GEL, US$ AND GBP TERMS, RESPECTIVELY STRONG NAV PER SHARE GROWTH 44.32 46.84 48.12 54.48 63.03 65.56 73.28 82.94 95.95 154.68 154.82 175.12 Dec-18 Dec-19 Dec-20 Jun-21 Dec-21 Dec-22 Jun-23 Dec-23 Dec-24 Dec-25 Mar-26 Jun-26 NAV PER SHARE (GEL) DEVELOPMENT OVERVIEW CAGR since the demerger: 20.1% 5 Five-year CAGR: 26.3% Three-year CAGR: 33.7% ✓ SUSTAINED NAV PER SHARE DEVELOPMENT REINFORCES OUR LONG-TERM VALUE GROWTH PROPOSITION FOR OUR SHAREHOLDERS ✓ GEORGIA CAPITAL HAS BEEN AMONG THE BEST-PERFORMING STOCKS IN THE UK INVESTMENT COMPANIES SECTOR OVER THE PAST THREE AND FIVE YEARS, DELIVERING SHARE PRICE CAGR OF 65.0% AND 45.7%, RESPECTIVELY

Page 6

6 NET CAPITAL COMMITMENT (NCC) OVERVIEW NCC RATIO DOWN BY 6.8 PPTS TO ITS RECORD-LOW LEVEL AS OF 30-JUN-26 The improvement was supported by: ✓ robust cash generation ✓ continued portfolio value growth ✓ strengthened risk profile of the Group -5.7% -0.9% 0.3% -0.8% 0.3% NCC 31-Mar-26 Increase in net cash Decrease in announced buybacks Change in planned investments Change in contingency buffer Increase in portfolio value NCC 30-Jun-26 2.3% -6.8 ppts DRIVERS OF Q-O-Q CHANGE IN NCC 3.9% 3.9% OVER THE CYCLE TARGET OF 10% -2.9% 3.6% -2.9% GCAP’S EXCELLENT FINANCIAL POSITION AND PRUDENT FINANCIAL POLICY WAS RECOGNISED BY S&P GLOBAL RATINGS, WHICH UPGRADED GCAP’S CREDIT RATING TO BB (STABLE) FROM BB- (POSITIVE), ALIGNING GCAP WITH THE SOVEREIGN CREDIT RATING OF GEORGIA

Page 7

42.5% 39.8% 31.9% 21.1% 15.6% 12.8% 2.3% -2.9% 10.0% 345.7 365.9 385.8 250.1 213.6 171.3 42.8 (59.3) 31-Dec-19 31-Dec-20 31-Dec-21 31-Dec-22 31-Dec-23 31-Dec-24 31-Dec-25 30-Jun-26 Target NCC ratio Net Capital Commitment (US$ million) 7 NCC RATIO DEVELOPMENT OVERVIEW Over the cycle Target NCC AND NCC RATIO DEVELOPMENT OVERVIEW1 OVER THE CYCLE TARGET NCC REPRESENTS AN AGGREGATED VIEW OF ALL CONFIRMED, AGREED AND EXPECTED CAPITAL OUTFLOWS AT THE GCAP HOLDCO LEVEL Georgia Capital PLC | 1. Reflects the retrospective conversion of the loans issued to our other businesses into equity. -5.2 ppts

Page 8

8 LEVERAGE OVERVIEW OF OUR PRIVATE BUSINESSES GCAP’S DELEVERAGING STRATEGY HAS PUT THE PORTFOLIO IN ITS STRONGEST BALANCE-SHEET POSITION TO DATE Georgia Capital PLC | General note: Figures for retail (pharmacy) and healthcare services businesses are given excluding IFRS 16 effects. Net debt includes the application of the minority buyout agreement in the retail (pharmacy) business and assumes the reclassification of the loans issued to our real estate business as quasi-equity facilities throughout 2019 - 2021. All figures are given excluding beer and distribution business. For renewable energy business, figures are calculated in US$ terms. 1. LTM EBITDA excludes the gain of GEL 2.9 million from the sale of one of the polyclinics buildings in 3Q23. 2. Incorporates disposal of Batumi Hospital. 3. Medical insurance is given including Ardi. 4. Excludes the housing development business, which was divested in June 2026. GEL MILLION 195 220 249 222 219 221 214 240 281 309 333 351 353 958 934 852 877 758 748 816 908 873 853 894 881 747 4.9x 4.3x 3.4x 3.9x 3.5x 3.4x 3.8x 3.8x 3.1x 2.8x 2.7x 2.5x 2.1x Dec-19 Dec-20 Dec-21 Jun-22 Dec-22 Jun-23 Dec-23 Jun-24 Dec-24 Jun-25 Dec-25 Mar-26 Jun-26 Total LTM EBITDA Total Net debt Total Net debt/EBITDA 1,2,3 3 3 3 3 3, 41,2 ➢ NET DEBT/EBITDA DECLINED FROM 4.9x AS OF DEC-19 TO ITS LOWEST LEVEL OF 2.1x AS OF JUN-26 ➢ TOTAL NET DEBT DECREASED BY 22.0% AS OF JUN-26 COMPARED TO ITS LEVEL AS OF DEC-19 ➢ LTM EBITDA INCREASED BY 80.4% AS OF JUN-26 COMPARED TO DEC-19

Page 9

9 LEVERAGE OVERVIEW OF OUR LARGE BUSINESSES 0.0x 0.5x 0.4x 0.2x 1.0x 31-Dec-23 31-Dec-24 31-Dec-25 30-Jun-26 Allowed 2.2x 1.9x 1.3x 0.8x 2.0x 31-Dec-23 31-Dec-24 31-Dec-25 30-Jun-26 Allowed 5.0x 4.3x 3.7x 3.5x 3.0x 31-Dec-23 31-Dec-24 31-Dec-25 30-Jun-26 Allowed HEALTHCARE SERVICES ALLOWED LEVERAGE RETAIL (PHARMACY) INSURANCE BELOW LIMIT ALLOWED LEVERAGE ALLOWED LEVERAGE ABOVE LIMIT BELOW LIMIT NO LEVERAGE NET DEBT TO EBITDA DEVELOPMENT OVERVIEW

Page 10

SHARE BUYBACK AND CANCELLATION PROGRAMME 16.7 MILLION SHARES (US$ 295 MILLION IN VALUE) REPURCHASED AND CANCELLED SINCE DEMERGER IN 2018, REPRESENTING 35.0%1 OF THE ISSUED SHARE CAPITAL AT ITS PEAK DEVELOPMENT OF GCAP’S SHARE BUYBACK AND CANCELLATION PROGRAMMES Georgia Capital PLC | 1. Determined by taking into account the peak number of 47.9 million shares issued as of 31-Dec-20. 2. Represents shares issued during Georgia Healthcare Group (“GHG”) share exchange facility. $18 $36 $36 $43 $61 $80 $128 $239 $295 1.3 2.7 2.7 3.5 5.8 7.4 11.1 15.6 16.7 2018 Since demerger 2019 2020 2021 2022 2023 2024 2025 2026 to date Value of shares repurchased (cumulative, US$ million) Number of shares repurchased (cumulative, million) 39.4 40.2 47.92 47.1 44.8 43.2 39.5 34.9 33.8 Number of issued shares (million) ➢ Repurchased c.476,000 shares for a total consideration of GEL 68.5 million (US$ 25.5 million) in 2Q26 ➢ c.1,095,000 shares (US$ 55.6 million in value) repurchased to date in 2026, representing 3.1% of issued share capital as at the beginning of 2026 10

Page 11

EARLY BOND REDEMPTION OF US$ 150 MILLION GEL 413 MILLION REPURCHASED & CANCELLED SHARES GEL 270 MILLION GEL 700 MILLION CAPITAL RETURN PROGRAMME CURRENTLY ONGOING SHARE BUYBACK GEL 28 MILLION THE EARLY COMPLETION OF THE CAPITAL RETURN PROGRAMME ONCE AGAIN DEMONSTRATES GCAP'S STRONG CASH FLOW GENERATION AND DISCIPLINED CAPITAL ALLOCATION TOGETHER, UPON COMPLETION OF THE CURRENT SHARE BUYBACK PROGRAMME, THESE TRANSACTIONS WILL MARK THE COMPLETION OF GCAP'S GEL 700 MILLION CAPITAL RETURN PROGRAMME, SIGNIFICANTLY AHEAD OF ITS ORIGINAL DECEMBER 2027 TIMELINE IN JUNE 2026, GCAP ANNOUNCED: COMPLETION OF GEL 700 MILLION CAPITAL RETURN PROGRAMME THE FULL EARLY REDEMPTION OF THE US$ 50 MILLION SUSTAINABILITY- LINKED LOCAL BONDS ISSUED BY ITS GEORGIAN HOLDING COMPANY. SETTLEMENT IS EXPECTED ON 19 AUGUST 2026, FOLLOWING WHICH GCAP WILL HAVE FULLY REPAID ITS OUTSTANDING HOLDING COMPANY DEBT AN EXTENSION OF ITS CURRENT SHARE BUYBACK AND CANCELLATION PROGRAMME, OF WHICH APPROXIMATELY US$ 11 MILLION REMAINS OUTSTANDING 2 1 11

Page 12

12 ROBUST CASH GENERATION 211 302 48 8 (69) 500 (190) 310 Cash and liquid funds 31-Mar-26 LFG sell-down Dividend Income Investments/ divestments Share repurchases Cash and liquid funds 30-Jun-26 Bond redemption and buyback extension Pro-forma cash and liquid funds 2.3% KEY DRIVERS OF CHANGE IN CASH AND LIQUID FUNDS CASH AND LIQUID FUNDS BALANCE UP 2.4X TIMES OVER THE QUARTER THE INCREASE WAS PRIMARILY DRIVEN BY: ✓ SELL-DOWN OF LION FINANCE GROUP SHARES IN LINE WITH OUR PFIC RISK MANAGEMENT STRATEGY ✓ SOLID DIVIDEND INCOME ✓ DISPOSAL OF HOUSING DEVELOPMENT BUSINESS GCAP’S STRONG CURRENT AND EXPECTED LIQUIDITY POSITION, COUPLED WITH A REDUCED RISK PROFILE, CREATES OPPORTUNITIES FOR FURTHER CAPITAL RETURNS AND GROWTH INVESTMENTS GEL MILLION following the US$ 50 million SLB redemption and US$ 10 million buyback extension c.310

Page 13

LAUNCH OF NEW GEL 1 BILLION CAPITAL ALLOCATION PROGRAMME 13 THE PROGRAMME IS UNDERPINNED BY GCAP’S DERISKED AND STRENGTHENED BALANCE SHEET, WITH NO HOLDCO-LEVEL BORROWINGS AND SUSTAINED NAV PER SHARE GROWTH IT IS EXPECTED TO BE FUNDED THROUGH A COMBINATION OF: ✓ EXISTING STRONG LIQUID FUNDS ✓ EXPECTED ROBUST FREE CASH FLOW GENERATION AT GCAP o Dividend inflows from Lion Finance Group o Dividend inflows from private portfolio companies THE PROGRAMME COVERS: GCAP ANNOUNCES THE LAUNCH OF A NEW GEL 1 BILLION CAPITAL ALLOCATION PROGRAMME, EXPECTED TO BE IMPLEMENTED AND COMPLETED BY THE END OF 2029 BUSINESS INVESTMENTS IN GEORGIA AND ARMENIA CAPITAL RETURNS - SHARE BUYBACKS AND POTENTIAL DIVIDENDS THE NEW PROGRAMME WILL COMMENCE FOLLOWING THE COMPLETION OF THE CURRENT SHARE BUYBACK PROGRAMME, STARTING WITH AN INITIAL US$ 50 MILLION SHARE BUYBACK PROGRAMME THE BOARD EXPECTS THAT AT LEAST HALF OF THE PROGRAMME WILL BE ALLOCATED TO CAPITAL RETURNS - SHARE BUYBACKS AND/OR DIVIDENDS

Page 14

RESILIENT MACROECONOMIC PERFORMANCE DESPITE UNCERTAINTIES 14 GEORGIA’S ECONOMY STARTED 2026 WITH STRONG MOMENTUM, POSTING 7.9% GDP GROWTH IN 1H26 Georgia Capital PLC | Source: Geostat, NBG GROSS INTERNATIONAL RESERVES PEAKED AT A RECORD HIGH OF US$ 7.1 BN IN JUNE 2026, UP BY 52% Y-O-Y INFLATION IS EXPECTED TO STAY RELATIVELY HIGH IN 2026, MAINLY DRIVEN BY HIGHER OIL AND FOOD PRICES 49.7 104.6 4.7 4.3 5.1 6.7 8.3 9.2 10.3 5.4% -6.3% 10.6% 11.0% 7.8% 9.7% 7.5% 9.0% 7.0% -15 5 25 45 65 85 105 2019 2020 2021 2022 2023 2024 2025 1Q26 2Q26* Nominal GDP, GEL bln (LHS) GDP Per Capita, USD THS (LHS) Real GDP, YoY % (RHS) 73 100 265 430 164 34 26 -48 -301 -461 -598 -332 -214 147 64 438 -102 -778 -837 -500 -1,579 3.5 3.6 3.4 3.8 4.1 4.3 3.9 4.3 4.7 4.3 6.2 7.1 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 NBG Net Interventions, US$ mln (RHS) Reserve Assets,EoP,US$ bln (LHS) THE CURRENT ACCOUNT DEFICIT REMAINED LOW AT 3.8% OF GDP IN 1Q26, REFLECTING BROAD- BASED IMPROVEMENTS ACROSS ALL COMPONENTS -6.7% -6.0% -12.4% -10.3% -4.4% -5.5% -5.3% -2.6% -7.9% -3.8% 7.5% 7.8% 3.7% 6.7% 8.9% 6.3% 4.6% 4.4% 0 2.3% 3.0% -28% -18% -8% 2% 12% 22% 2018 2019 2020 2021 2022 2023 2024 2025 1Q25 1Q26 Goods, net Services, net Investment income, net Current transfers, net Current account FDI, inflows 5.8 3.5 8.25 0 2 4 6 8 10 12 14 Feb-22 Apr-22 Jun-22 Aug-22 Oct-22 Dec-22 Feb-23 Apr-23 Jun-23 Aug-23 Oct-23 Dec-23 Feb-24 Apr-24 Jun-24 Aug-24 Oct-24 Dec-24 Feb-25 Apr-25 Jun-25 Aug-25 Oct-25 Dec-25 Feb-26 Apr-26 Jun-26 Headline Inflation Core Inflation Target Monetary Policy Rate *Preliminary estimated real GDP growth.

Page 15

Page 16

119 148 1H25 1H26 62 75 2Q25 2Q26 16 AGGREGATED REVENUE AND EBITDA DEVELOPMENT ACROSS LARGE PRIVATE PORTFOLIO AGGREGATED REVENUE DEVELOPMENT GEL MILLION AGGREGATED EBITDA DEVELOPMENT GEL MILLION439 523 869 1,012 2Q25 2Q26 1H25 1H26 +19.1% +16.4% +21.2% +23.9%

Page 17

14.3% 13.4% 11.4% 13.7% 19.1% 11.9% 11.4% 12.9% 11.5% 11.8% 2Q25 3Q25 4Q25 1Q26 2Q26 y-o-y revenue growth of large portfolio companies y-o-y nominal GDP growth 17 SUSTAINED DOUBLE-DIGIT AGGREGATED REVENUE GROWTH OF PRIVATE LARGE PORTFOLIO COMPANIES AGGREGATED REVENUE DEVELOPMENT ACROSS OUR PRIVATE LARGE PORTFOLIO AGGREGATE REVENUES OF OUR LARGE PRIVATE PORTFOLIO COMPANIES UP BY 19.1% Y-O-Y IN 2Q26, MARKING THE EIGHTH CONSECUTIVE QUARTER OF DOUBLE-DIGIT REVENUE GROWTH AGAINST THE BACKDROP OF CONTINUED ECONOMIC GROWTH IN GEORGIA, WITH NOMINAL GDP GROWTH PRELIMINARILY ESTIMATED AT 11.8% Y-O-Y IN 2Q26, OUR LARGE PRIVATE PORTFOLIO COMPANIES DELIVERED ANOTHER QUARTER OF STRONG GROWTH RELATIVE TO THE BROADER ECONOMY DOUBLE-DIGIT REVENUE GROWTH FOR THE EIGHTH CONSECUTIVE QUARTER

Page 18

AGGREGATED CASH BALANCE & NET OPERATING CASH FLOW DEVELOPMENT ACROSS LARGE PRIVATE PORTFOLIO AGGREGATED NET OPERATING CASH FLOW AGGREGATED CASH BALANCE 18 54 76 2Q25 2Q26 +41.4% 97 132 1H25 1H26 +36.2% 210 238 254 30-Jun-25 31-Mar-26 30-Jun-26 +6.8% +21.1% GEL MILLION GEL MILLION

Page 19

01 2Q26 & 1H26 PERFORMANCE OVERVIEW 02 DEEP DIVE INTO PRIVATE LARGE PORTFOLIO COMPANIES RETAIL (PHARMACY) BUSINESS OVERVIEW HEALTHCARE SERVICES BUSINESS OVERVIEW INSURANCE BUSINESS OVERVIEW 03 2Q26 & 1H26 PORTFOLIO VALUATION OVERVIEW 04 LIQUIDITY AND DIVIDEND INCOME OUTLOOK 05 WRAP-UP 06 ANNEX CONTENTS 19 19

Page 20

RETAIL (PHARMACY) BUSINESS OVERVIEW 20 GEORGIA’S LARGEST RETAILER IN TERMS OF REVENUE WITH 34% MARKET SHARE IN ORGANISED RETAIL MARKET1 Georgia Capital PLC | 1. Based on 2024 revenues. 2. Includes 2 pharmacy chains. 3. In 2026, revenue generated under state-funded programmes and sold through retail channels has been reclassified from wholesale to retail revenue, considering that retail serves as the distribution channel for such sales. Comparative periods and respective operating data have been restated accordingly. RETAIL BUSINESS PORTFOLIO | JUNE 2026 Pharmacies in total +6 Q-O-Q 464 20 in Armenia 444 in Georgia 14 The Body Shop stores 7 in Georgia 2 in Armenia 5 in Azerbaijan ✓ In 2Q26, the retail pharmacy chain expanded by 6 pharmacies, with openings focused on strategically selected locations 5 Optics – Alain Afflelou 1 in Armenia 4 in Georgia ORGANISED RETAIL MARKET SHARE | 2024 REVENUE 6% 30% 34% 30% 125.3 624.6 633.7 PHARMADEPOT - 482.6 GPC – 219.9 Other² PSP Aversi GCAP in pharma 702.5 GEL MILLION GCAP’s retail (pharmacy) business 189 215 380 422 35 41 70 78 224 256 450 500 2Q25 2Q26 1H25 1H26 Retail Wholesale +14.1% 32.5% 34.0%32.7% 34.1% Gross Profit Margin +13.7% +11.6% REVENUE DEVELOPMENT, GEL MILLION3 +11.2% 17.1 17.28.4 8.8 Number of bills issued (million) 22.4 24.5 22.2 24.5 2Q25 2Q26 1H25 1H26 +9.3% +10.1% AVERAGE BILL SIZE, GEL3 SAME STORE REVENUE GROWTH3 1H26 RETAIL REVENUE BY CATEGORIES +16.5% +11.1% 2Q25 7.9% 2Q26 8.5% 1H25 5.3% 1H26 6.5% GEL 422 MILLION PRESCRIPTION 31% OVER THE COUNTER 24% FOOD SUPPLEMENT 12% BABY CARE & FOOD 10% COSMETICS & OTHER 23% BEAUTY & OTHER 45% GEL 189 MLN MEDICINE 55% GEL 233 MLN

Page 21

RETAIL (PHARMACY) BUSINESS PERFORMANCE OVERVIEW (CONT’D) 21 GEL MILLION EBITDA EBITDA margin 24.4 29.8 48.5 58.9 2Q25 2Q26 1H25 1H26 10.9% 11.7% 10.8% 11.8% +22.3% +21.4% ✓ ACHIEVED Y-O-Y EBITDA GROWTH OF 22.3% IN 2Q26 OPERATING CASH FLOW EBITDA to cash conversion 63.8% 88.1% 89.3% 100.9% ✓ EBITDA TO CASH CONVERSION STOOD AT 88.1% IN 2Q26, REFLECTING THE STRONG BUSINESS PERFORMANCE 15.5 26.2 43.3 59.5 2Q25 2Q26 1H25 1H26 +69.0% +37.2% ADJUSTED NET DEBT TO LTM EBITDA1 Georgia Capital PLC | General note: Figures are given excluding IFRS 16 effect; 1. Figures take into account the application of the minority buyout agreement. 136.7 130.3 128.3 102.5 94.5 1.4x 1.3x 1.3x 1.0x 0.8x 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 Jun-25 Sep-25 Dec-25 Mar-26 Jun-26 Adjusted net debt Adjusted net debt to LTM EBITDA ✓ ADJUSTED NET DEBT TO LTM EBITDA STANDS AT 0.8x AS OF JUNE 2026, BELOW THE TARGETED LEVEL OF 1.5x ✓ GEL 11.9 MILLION DIVIDENDS PAID TO GCAP IN 2Q26

Page 22

3 ROBUST CASH GENERATION REFLECTED IN 88.1% EBITDA-TO-CASH CONVERSION AND PRUDENT LEVERAGE WITH ADJUSTED NET DEBT TO EBITDA AT 0.8x. THE BUSINESS DISTRIBUTED GEL 11.9 MILLION DIVIDENDS TO GCAP IN 2Q26 (GEL 10.0 MILLION IN 2Q25) 2 ENHANCED PROFITABILITY, SUPPORTED BY A SHIFT IN THE SALES MIX TOWARD HIGHER-MARGIN PRODUCT PORTFOLIO AND IMPROVED SUPPLIER TERMS, DRIVING SIGNIFICANT GROSS PROFIT AND EBITDA GROWTH 1 STRONG TOP-LINE PERFORMANCE SUPPORTED BY 8.5% SAME-STORE REVENUE GROWTH IN 2Q26 AND ROBUST PERFORMANCE OF WHOLESALE BUSINESS 22 RETAIL (PHARMACY) BUSINESS KEY CONSIDERATIONS

Page 23

Page 24

55 67 107 12763 73 127 143 - 50 100 150 200 250 300 2Q25 2Q26 1H25 1H26 outpatient inpatient 3.9 3.8 3.7 3.7 3.5 0 2 4 6 8 10 83 90 93 97 103 0 50 100 150 Jun-25 Sep-25 Dec-25 Mar-26 Jun-26 24 30 47 57 0 10 20 30 40 50 60 2Q25 2Q26 1H25 1H26 HEALTHCARE SERVICES BUSINESS OVERVIEW 24 2Q26 AND 1H26 KEY HIGHLIGHTS: GEL MILLION EBITDA1NET REVENUE +20.4% Georgia Capital PLC | 1. EBITDA, net debt and EBITDA margin (%) are presented excluding IFRS 16 impact. HEALTHCARE BUSINESS PORTFOLIO ✓ EXPANDED SERVICE OFFERINGS ACROSS TBILISI AND THE REGIONS ✓ NEW DOCTORS ONBOARDED ✓ LAB RETAIL NETWORK FURTHER EXPANDED, REACHING 20 TOTAL RETAIL BRANCHES ✓ NET REVENUE FROM OUTPATIENT SERVICES UP 21.6% AND 18.6% Y-O-Y IN 2Q26 AND 1H26, RESPECTIVELY ✓ DELIVERED 16% TOP-LINE AND 20% EBITDA GROWTH Y-O-Y IN 1H26 LTM EBITDA AND NET DEBT TO LTM EBITDA1 GEL MILLION +15.9% 118 JUNE 2026 Hospitals 35 16 Polyclinics 1 Laboratory WC/Revenue, % 21.5% 17.9% +25.1% x x x x x +17.9% 139 234 271 15.8% 17.0% 19.5% 20.7% 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% FY23 FY24 FY25 1H26 EBITDA MARGIN1

Page 25

69.1% 71.1% 72.2% 69.7% 62.0% 64.0% 66.0% 68.0% 70.0% 72.0% 74.0% 76.0% 78.0% 80.0% 2Q25 2Q26 1H25 1H26 18 23 37 43 - 10 20 30 40 50 2Q25 2Q26 1H25 1H26 16 19 24 27 - 10 20 30 2Q25 2Q26 1H25 1H26 97 114 191 222 - 50 100 150 200 250 2Q25 2Q26 1H25 1H26 25 HOSPITALS BUSINESS 2Q26 AND 1H26 KEY HIGHLIGHTS: GEL MILLIONGEL MILLION Georgia Capital PLC | 1. EBITDA and operating cash flow are presented excluding IFRS 16 impact. 2. Operating highlights include preliminary operating data from Gormed. OPERATING HIGHLIGHTS - BED OCCUPANCY RATES (%) Average length of stay (days) NET REVENUE EBITDA1 OPERATING CASH FLOWS1 +18.3% +17.0% 10,366 308 497 779 813 839 2,460 Other Ingorokva Tbilisi Medical Institute Ghudushauri-Chachava Geo Hospitals Aversi State GCAP Hospitals HOSPITALS MARKET SHARES | NUMBER OF HOSPITAL BEDS* 65% 2% 3% 5% 5% 5% 15% *Total number of beds amounts to 16,062 HEALTHCARE SERVICES BUSINESS PERFORMANCE OVERVIEW 4.4 3.9 87.9% 62.6% EBITDA to cash conversion (excl. IFRS 16) 2 EBITDA margin (excl. IFRS 16) ✓ Revenue growth of 18% in 2Q26, supported by expansion of outpatient services, which increased by 21% ✓ Operating cash flow reflects seasonality patterns in state cash collections ✓ Average length of stay reduced by 0.6 days (1H26 vs 1H25) 18.7% 19.8%+16.2% +23.9% +17.9% 18.9% 19.2% +14.0% 83.0% 64.8% -2.5 ppts 3.9 4.5 +2.0 ppts WC/Revenue, % 22.4% 19.7%

Page 26

3.6 4.2 7.8 8.3 - 2.0 4.0 6.0 8.0 10.0 2Q25 2Q26 1H25 1H26 485 513 988 1,003 - 500 1,000 1,500 2Q25 2Q26 1H25 1H26 5 7 11 13 - 2 4 6 8 10 12 14 16 2Q25 2Q26 1H25 1H26 23 27 46 53 - 10 20 30 40 50 60 2Q25 2Q26 1H25 1H26 HEALTHCARE SERVICES BUSINESS PERFORMANCE OVERVIEW (CONT’D) 26 CLINICS & DIAGNOSTICS 2Q26 AND 1H26 KEY HIGHLIGHTS: GEL MILLIONGEL MILLION Georgia Capital PLC | 1. EBITDA and operating cash flow are presented excluding IFRS 16 impact. OPERATING HIGHLIGHTS EBITDA1 OPERATING CASH FLOWS1 NUMBER OF ADMISSIONS (THOUSANDS) - POLYCLINICS NUMBER OF TESTS PERFORMED (MILLION) - DIAGNOSTICS +16.8% +26.4% +16.6% +5.7% 136,828 323,910 416,452 423,723 Other Medcapital Geo Hospitals GCAP Polyclinics GCAP Regional & Community Clinics CLINICS MARKET SHARES | NUMBER OF REGISTERED PATIENTS 59% 4% 14% 1,809,453 13% 10% *Total number of registered patients amounts to 3,110,366 22.8% 24.7% EBITDA margin (excl. IFRS 16) 67.2% 61.4% EBITDA to cash conversion (excl. IFRS 16) 27% ✓ Number of admissions in polyclinics increased by 6% y-o-y in 2Q26 ✓ Number of registered patients in polyclinics increased by c.10,000 y-o-y ✓ Net revenue grew by 17% y-o-y in 2Q26 ✓ EBITDA growth amounted to 26% y-o-y in 2Q26 GCAP Polyclinics GCAP Regional & Community Clinics +15.4% NET REVENUE +27.4% 23.0% 25.4% +5.8% 62.0% 73.9% +1.5% 0.7 0.7 1.4 1.4 - 1.0 2.0 2Q25 2Q26 1H25 1H26 +3.6% +3.5% WC/Revenue, % 6.1% 8.5%

Page 27

27 2 1 EXPANDED MEDICAL INFRASTRUCTURE, STRENGTHENED CLINICAL TEAMS AND ADDED NEW COMPLEX SURGICAL AND OTHER SERVICES WITHIN GHG NETWORK DELIVERED 18% Y-O-Y TOP-LINE GROWTH IN 2Q26 3 HEALTHCARE SERVICES BUSINESS KEY CONSIDERATIONS EBITDA GROWTH AMOUNTED TO 25%, WITH EBITDA MARGIN IMPROVING BY 1.4 PPTS Y-O-Y IN 2Q26

Page 28

Page 29

44 49 53 79 2Q-25 2Q-26 P&C Medical 29 INSURANCE BUSINESS OVERVIEW INSURANCE BUSINESS COMPRISES TWO BUSINESS LINES: INSURANCE REVENUE GEL MILLION +32% GEL MILLION +34% ADJUSTED PRE-TAX PROFIT1, 2 PROPERTY AND CASUALTY (P&C) KEY OPERATING HIGHLIGHTS 2Q26 CHANGE y-o-y 1H26 CHANGE y-o-y NPW, P&C 62 21% 105 15% NPW, Medical 69 55% 223 68% NPW, Total Insurance 131 37% 327 47% 97 128 GEL MILLION Georgia Capital PLC | 1. Excluding ARDI acquisition-related interest expense allocation to medical insurance business. 2. The figures are presented excluding GEL 3.0 million motor insurance claims’ effect following a severe hailstorm in Tbilisi. 2Q25 2Q26 82 92 104 149 6M25 6M261H25 1H26 +30% 186 241 MEDICAL 9 8 5 8 2Q-25 2Q-26 P&C Medical GEL MILLION +13% PRE-TAX PROFIT1 14 16 2Q25 2Q26 16 17 8 16 6M25 6M261H25 1H26 +36% 24 32 9 11 5 8 2Q25 2Q26 14 19 16 20 8 16 1H25 1H26 +49% 24 36

Page 30

44 49 2Q-25 2Q-26 16 17 6M25 6M26 9 8 2Q-25 2Q-26 82 92 6M25 6M26 18% 2% 9% 18% 24% 29% INSURANCE BUSINESS OVERVIEW – P&C INSURANCE 30 ALDAGI IS A LEADING PLAYER IN PROPERTY AND CASUALTY INSURANCE INSURANCE REVENUE ✓ THE Y-O-Y INCREASE IN 2Q26 REVENUE REFLECTS: 1) INCREASE IN PROPERTY INSURANCE REVENUES DUE TO THE EXPANSION IN CORPORATE CLIENT PORTFOLIO, 2) GROWTH IN CREDIT LIFE INSURANCE LINE, AND 3) EXPANSION OF RETAIL AND CORPORATE MOTOR PORTFOLIOS, COUPLED WITH INCREASE IN CORPORATE INSURANCE POLICY PRICES PRE-TAX PROFIT (GEL MILLION) ✓ THE Y-O-Y INCREASE IN 2Q26 COMBINED RATIO PRIMARILY REFLECTS GEL 3.0 MILLION OF MOTOR INSURANCE CLAIMS ARISING FROM THE SEVERE HAILSTORM IN TBILISI. EXCLUDING T HIS ONE-OFF EVENT, THE 2Q26 COMBINED RATIO WOULD HAVE IMPROVED BY 1.5 PPTS Y-O-Y TO 82.9% GEL MILLION +11% 36.1% 27.5% -11% (+23% 1) GEL MILLION ROAE 2Q26 CHANGE Y-O-Y 1H26 CHANGE Y-O-Y NPW (GEL million) 62 21% 105 15% Combined Ratio 89.2% 4.8 ppts 87.6% 1.7 ppts Combined Ratio1 82.9% -1.5 ppts 84.2% -1.7 ppts Individuals Insured 144K 11% 144K 11% Policies Written 132K 29% 240K 22% Retail Renewal 79.6% 3.3 ppts 79.9% 2.1 ppts P&C MARKET SHARES | 1Q26 GROSS PREMIUMS WRITTEN (GEL MILLION) KEY OPERATING METRICS 1H25 1H26 37 4 20 38 49 60 Other Unison Global Benefits Georgia Vienna Insurance Group TBC Insurance P&C BusinessP&C Business ✓ P&C MARKET SHARE TENDS TO BE LOWER IN THE FIRST QUARTER, AS THE LARGE ACCOUNTS OF THE PORTFOLIO ARE PREDOMINANTLY RENEWED IN THE UPCOMING QUARTERS 32.4% 29.9% +6% (+25%1) 2Q25 2Q26 +12% 1H25 1H262Q25 2Q26 ✓ EXCLUDING HAILSTORM EVENT-RELATED MOTOR INSURANCE CLAIMS OF GEL 3.0 MILLION, P&C INSURANCE BUSINESS WAS UP BY 23% AND 25% Y-O-Y IN 2Q26 AND 1H26, RESPECTIVELY ✓ GEL 6.3 MILLION DIVIDENDS WERE PAID TO GCAP IN 2Q26 (GEL 11.6 MILLION IN 1H26) FLAT Y-O-Y Georgia Capital PLC | 1. The figures are presented excluding GEL 3.0 million motor insurance claims’ effect following a severe hailstorm in Tbilisi.

Page 31

2Q26 CHANGE Y-O-Y NPW (GEL million) 69 55% Combined Ratio 92.2% -1.0 ppts Individuals Insured 372K 38% Renewal Rate 77.1% -5.3 ppts 104 149 6M25 6M26 53 79 2Q-25 2Q-26 INSURANCE BUSINESS OVERVIEW – MEDICAL INSURANCE Georgia Capital PLC | 1. Excluding ARDI acquisition-related interest expense allocation to medical insurance business. 31 ✓ THE Y-O-Y IMPROVEMENT IN THE 2Q26 COMBINED RATIO MAINLY REFLECTS A LOWER EXPENSE RATIO AS HIGHER INSURANCE REVENUE IMPROVED OPERATING LEVERAGE MEDICAL INSURANCE MARKET SHARE | 1Q26 GROSS PREMIUMS WRITTEN GEL MILLION KEY OPERATING METRICS INSURANCE REVENUE GEL MILLION ✓ 49% Y-O-Y GROWTH IN 2Q26 REVENUES PRIMARILY REFLECTS NEWLY AWARDED TENDERS AND ORGANIC GROWTH IN THE CORPORATE PORTFOLIO, SUPPLEMENTED BY A MID-TEENS PERCENTAGE INCREASE IN INSURANCE POLICY PRICES AND RETAIL HEALTH PORTFOLIO EXPANSION 17% 8% 9% 17% 49% PRE-TAX PROFIT & ROAE 51 24 27 48 142 Other Global Benefits Georgia TBC Insurance Vienna Insurance Group Medical Insurane BusinessMedical Insurance Business ✓ MARKET SHARE INCREASED BY 16 PPTS Y-O-Y, PRIMARILY REFLECTING HIGHER MEDICAL TENDER PREMIUMS AND STRONG GROWTH IN THE RETAIL HEALTH SEGMENT DURING 1Q26 +49% +43% 1H25 1H262Q25 2Q26 GEL MILLION 5 8 2Q-25 2Q-26 8 16 6M25 6M26 32.6% 44.5%ROAE 24.6% 46.0% +53% +98% 1H26 CHANGE Y-O-Y 223 68% 91.7% -4.1 ppts 372K 38% 78.0% -3.6 ppts 1 ✓ TENDERS: • Medical tender premiums increased by GEL 13.8 million in 2Q26 (GEL 72.5 million in 1H26), reflecting tariff adjustments and enhanced underwriting criteria, with a positive impact on overall loss ratio and profitability ✓ RETAIL: • Retail health insured count reached 16,400, driving a GEL 1.6 million increase (+44%) in premiums in 2Q26 (GEL 4.4 million increase in 1H26, +60%) • The introduction of mandatory inbound travel insurance generated GEL 1.6 million GPW in 2Q26 (GEL 3.1 million in 1H26) and, given its low loss ratio, provided a profitable and diversifying contribution to retail health ✓ CORPORATE: • Mid-teens percentage increase in insurance tariffs supporting overall corporate profitability +16 PPTS Y-O-Y 2Q25 2Q26 1H25 1H26

Page 32

2 MEDICAL INSURANCE CONTINUED TO DELIVER STRONG 53% Y-O-Y GROWTH IN PROFIT, DRIVEN BY NEWLY AWARDED TENDERS, RETAIL HEALTH EXPANSION AND DISCIPLINED PRICING, SUPPORTING FURTHER IMPROVEMENT IN PROFITABILITY 3 TOTAL INSURANCE REVENUE GREW BY 32% Y-O-Y IN 2Q26, WHILE PRE-TAX PROFIT INCREASED BY 13% Y-O-Y DESPITE THE HAILSTORM IMPACT, DEMONSTRATING THE RESILIENCE OF THE DIVERSIFIED PORTFOLIO 1 UNDERLYING P&C PROFITABILITY REMAINED STRONG, WITH 2Q26 PROFIT IMPROVING BY 23% Y-O-Y, EXCLUDING THE GEL 3.0 MILLION ONE-OFF HAILSTORM-RELATED MOTOR CLAIMS 32 INSURANCE BUSINESS KEY CONSIDERATIONS 4 GEL 6.3 MILLION DIVIDENDS PAID TO GCAP IN 2Q26

Page 33

01 2Q26 & 1H26 PERFORMANCE OVERVIEW 02 DEEP DIVE INTO PRIVATE LARGE PORTFOLIO COMPANIES 03 2Q26 & 1H26 PORTFOLIO VALUATION OVERVIEW 04 LIQUIDITY AND DIVIDEND INCOME OUTLOOK 05 WRAP-UP 06 ANNEX CONTENTS 33 33

Page 34

PORTFOLIO VALUE AS OF 30-JUN-26 Georgia Capital PLC | 1. In 2Q26, valuation assessments of our retail (pharmacy), healthcare services, insurance, renewable energy, and education businesses were performed by third-party independent valuation firm, in line with International Private Equity Valuation (“IPEV”) guidelines, as part of the semi-annual independent valuation cycle for these businesses. 2. LTM implied EV/EBITDA multiples for retail (pharmacy) and healthcare services are presented including IFRS 16 as of 30-Jun-26. 78% OF OUR PORTFOLIO IS VALUED EXTERNALLY1 2,537 2,334 542 Listed Large Emerging and other PORTFOLIO BREAKDOWN GEL 5,413 MILLION 10% 47% 43% 2,537 1,035 688 611 542 Lion Finance Group Retail (pharmacy) Healthcare services Insurance Emerging and other businesses % SHARE IN TOTAL PORTFOLIO VALUE: LARGE PORTFOLIO COMPANIES GEL MILLION 10%11% 9.9x LTM P/E 13% 10.4x LTM EV/EBITDA2 47% GBP 113.3 PRICE ON LSE 19% MULTIPLE: 8.3x LTM EV/EBITDA2 97% OF OUR PORTFOLIO IS VALUED EXTERNALLY1 LISTED 34

Page 35

9.8x 10.1x 9.5x 9.9x 30-Jun-25 31-Dec-25 31-Mar-26 30-Jun-26 INSURANCE 8.2x 8.1x 8.0x 8.3x 30-Jun-25 31-Dec-25 31-Mar-26 30-Jun-26 RETAIL (PHARMACY) 9.9x 10.1x 10.1x 10.4x 30-Jun-25 31-Dec-25 31-Mar-26 30-Jun-26 HEALTHCARE SERVICES 3535 PRIVATE LARGE PORTFOLIO IMPLIED MULTIPLE DEVELOPMENT

Page 36

222 (8) 5,045 154 5,413 Portfolio value 31-Mar-26 Lion Finance Group Large portfolio companies Other portfolio companies Portfolio value 30-Jun-26 PORTFOLIO VALUE DEVELOPMENT IN 2Q26 GEL MILLION PORTFOLIO UP BY 7.3% Q-O-Q TO GEL 5.4 BILLION IN 2Q26 36 LISTED PORTFOLIO UP BY 6.5% PRIVATE PORTFOLIO VALUE UP BY 8.1% PRIVATE PORTFOLIO 2Q26 VALUE CREATION GEL million Retail (pharmacy) 124.0 Healthcare services 66.8 Insurance 48.4 Emerging and other businesses 0.2 Total 239.4 Emerging and other portfolio companies LFG VALUE DEVELOPMENT IN 2Q26 GEL million Value as of 31-Mar-26 2,383.1 Value creation 484.1 Sell-down (302.2) Dividends (27.6) Value as of 30-Jun-26 2,537.5 154

Page 37

HEALTHCARE SERVICES 3737 PRIVATE LARGE PORTFOLIO VALUATION OVERVIEW 923 47 4 62 1,035 Equity Value 31-Mar-26 EBITDA change Net debt change FX & Multiple change Equity value 30-Jun-26 569 16 (0) 26 611 Equity Value 31-Mar-26 Net income change Net debt change Multiple change Equity value 30-Jun-26 620 45 (3) 25 688 Equity Value 31-Mar-26 EBITDA change Net debt change FX & Multiple change Equity value 30-Jun-26 Georgia Capital PLC | General note: In 2Q26, valuation assessments of our retail (pharmacy), healthcare services, insurance, renewable energy, and education businesses were performed by third-party independent valuation firm, in line with International Private Equity Valuation (“IPEV”) guidelines, as part of the semi-annual independent valuation cycle for these businesses. RETAIL (PHARMACY) INSURANCE GEL MILLION 8.0x MULTIPLE 8.3x MULTIPLE 9.5x MULTIPLE 9.9x MULTIPLE 10.1x MULTIPLE 10.4x MULTIPLE Includes GEL 6.3m dividend +5.0% +0.4% +6.7%Impact +2.8% 0.0% +4.6%Impact+7.3% -0.5%Impact +4.0% Includes GEL 11.9m dividend

Page 38

Page 39

LIQUIDITY OUTLOOK 74 54 88 234 152 40 99 89 85 196 124 Dec-19 Dec-20 Dec-21 Jun-22 Dec-22 Dec-23 Dec-24 Dec-25 Mar-26 Jun-26 Pro-forma LIQUIDITY DEVELOPMENT OVERVIEW (US$ MILLION) 39 GROSS DEBT (US$ million) LIQUIDITY INCREASED 2.3x TIMES Q-O-Q, DRIVEN BY: ✓ SELL-DOWN OF LION FINANCE GROUP SHARES ✓ DIVIDEND COLLECTIONS ✓ RECEIPT OF PROCEEDS FROM THE HOUSING DEVELOPMENT BUSINESS WHICH WERE PARTIALLY OFFSET BY SHARE BUYBACKSCancellation of US$ 65 million GCAP Eurobond LIQUIDITY OUTLOOK Full redemption of GCAP Eurobond Cash receipt from the 80% water utility business sale Jun-26 2 Georgia Capital PLC | 1. The figure includes accrued interim dividends from LFG (ex-dividend date in December 2025, payment date in January 2026). 2. The figure includes accrued interim dividends from LFG (ex-dividend date in June 2026, payment date in July 2026). Early redemption of US$ 100 million local holding bonds 1 Pro-forma 300 300300 365 365 150 150 50 50 50 0 Full early redemption of local holding bonds Early full redemption of SLB and buyback extension

Page 40

29 15 41 81 72 107 38 - 44 50 33 24 44 30 60 53 55 57 86 25 73 30 74 94 180 179 226 2019 2020 2021 2022 2023 2024 2025 Dividend income from listed companies Buyback dividend Dividend income from private companies 2026 c.200 OUTLOOK c.114 DIVIDEND INCOME OUTLOOK RECURRING CASH DIVIDEND INCOME FROM PORTFOLIO COMPANIES 40 GEL 46.7 MILLION RECURRING DIVIDEND INCOME IN 2Q26 GEL MILLION DIVIDEND INCOME (GEL million) 2Q26 1H26 Lion Finance Group 27.6 61.8 of which, cash dividend 18.3 38.0 of which, buyback dividend 9.3 23.7 Retail (pharmacy) 11.9 11.9 P&C insurance 6.3 11.6 Auto service 1.0 1.0 TOTAL 46.7 86.3 1 Georgia Capital PLC | 1. In 2023 and 2024, GCAP received one-off non-recurring inflows of GEL 56.1 million and GEL 22.6 million, respectively. c.200 GEL MILLION SOLID DIVIDEND INCOME OUTLOOK IN 2026 1 2.11.6 4.1 4.3 6.5 Dividend income per share (GEL) INCLUDES 1Q26 DIVIDEND FROM LFG RECEIVED IN JULY 2026

Page 41

Page 42

PERFORMANCE HIGHLIGHTS ✓ • NAV per share up by 13.1% q-o-q to a record high of GEL 175.12 and up 15.6% q-o-q to GBP 50.10 in GBP terms • Accelerated revenue growth across our large private portfolio companies, with aggregate revenues up 19.1% y-o-y in 2Q26 • NCC ratio improved by 6.8 ppts q-o-q to a record-low -2.9% in 2Q26 ✓ Successful disposal of our housing development business, m2, one of Georgia’s leading residential real estate developers ✓ S&P Global Ratings upgraded GCAP’s corporate credit rating from BB- (Positive) to BB (Stable), bringing the rating fully in line with Georgia’s sovereign credit rating ✓ Completion of the GEL 700 million capital return programme significantly ahead of schedule and commencement of a new GEL 1 billion capital allocation programme with a launch of initial US$ 50 million buyback programme ✓ 0.6 million shares repurchased during 2Q26 and 3Q26 to date, bringing total shares bought back since the demerger to 16.7 million (US$ 295 million), representing 35.0% of GCAP’s peak issued share capital OUTLOOK  Delivering on our value growth story through consistent NAV per share growth and sustainable EBITDA growth across our large portfolio companies  Maintaining the NCC ratio below 10%  Strong economic growth outlook OUTSTANDING QUARTERLY PERFORMANCE 42

Page 43

Page 44

44 NAV PER SHARE DISCOUNT DEVELOPMENT OVERVIEW 13.05 13.53 14.81 13.78 12.46 7.41 8.41 9.18 10.81 9.97 12.45 14.16 15.10 12.92 14.78 18.55 20.12 21.41 22.12 23.44 24.23 26.48 22.10 22.82 27.14 29.80 33.61 37.25 42.44 43.34 50.10 21.8% 19.4% 26.4% 26.0% 26.0% 42.6% 44.7% 60.2% 50.0% 42.0% 42.2% 57.6% 52.8% 51.2% 59.0% 66.6% 63.7% 63.3% 62.4% 58.0% 57.8% 49.9% 55.7% 59.2% 55.8% 48.4% 42.8% 35.3% 27.0% 16.2% 16.6% Dec-18 Mar-19 Jun-19 Sep-19 Dec-19 Mar-20 Jun-20 Sep-20 Dec-20 Mar-21 Jun-21 Sep-21 Dec-21 Mar-22 Jun-22 Sep-22 Dec-22 Mar-23 Jun-23 Sep-23 Dec-23 Mar-24 Jun-24 Sep-24 Dec-24 Mar-25 Jun-25 Sep-25 Dec-25 Mar-26 Jun-26 NAV Per Share (GBP) NAV Discount DESPITE STRONG RECENT TRADING PERFORMANCE, THE PRIVATE PORTFOLIO NAV PER SHARE DISCOUNT REMAINS WIDE, PRESENTING AN ATTRACTIVE BUYBACK OPPORTUNITY +19.6% CAGR

Page 45

Page 46

FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements, including, but not limited to, statements concerning expectations, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, competitive strengths and weaknesses, plans or goals relating to financial position and future operations and development. Although Georgia Capital PLC believes that the expectations and opinions reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations and opinions will prove to have been correct. By their nature, these forward-looking statements are subject to a number of known and unknown risks, uncertainties and contingencies, and actual results and events could differ materially from those currently being anticipated as reflected in such statements. Important factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements, certain of which are beyond our control, include, among other things: regional instability; currency fluctuations and risk, including depreciation of the Georgian Lari, and macroeconomic risk, regulatory risk across a wide range of industries; investment risk; liquidity risk; portfolio company strategic and execution risks and other key factors that could adversely affect our business and financial performance, which are contained elsewhere in this presentation and in our past and future filings and reports and also the 'Principal Risks and Uncertainties' included in the 1H26 Results Announcement and in Georgia Capital PLC’s Annual Report and Accounts 2025. No part of this document constitutes, or shall be taken to constitute, an invitation or inducement to invest in Georgia Capital PLC or any other entity and must not be relied upon in any way in connection with any investment decision. Georgia Capital PLC and other entities undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required. Nothing in this document should be construed as a profit forecast. 46

Slides